Ghent, Belgium – 15 November 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...

Ghent, Belgium – 19 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease and ...

Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, announces the completion of enrollment in its phase 2a SAHARA proof-of-concept study ...

Having delivered clinical proof-of-concept for DSR as a disease-modifying drug program for the treatment of heart failure, the Company is planning to commence MOJAVE, a US randomized controlled ...

First patient dosed successfully in YUKON, Ph. 1 study of second-generation DSR product (DSR 2.0) MOJAVE, US Ph. 1/2a randomized controlled multi-center study of DSR 2.0, on track to start in H1 2023 ...

Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

At the start of the study treatment period, loop diuretics were withheld, and patients underwent intensive DSR therapy with DSR 1.0 for two weeks (phase 1) which was repeated up to two times depending ...